Recursion’s Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation has Fully Enrolled
June 13, 2023 08:00 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, June 13, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced the full...
Recursion to Participate in Upcoming Investor Conferences
June 01, 2023 08:30 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, June 01, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a clinical stage TechBio company decoding biology to industrialize drug discovery, today announced its participation in...
Altitude Lab Relocates to Gateway’s BioHive Hub
May 25, 2023 16:00 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, May 25, 2023 (GLOBE NEWSWIRE) -- Altitude Lab announced today that its incubator program and facility will leave Research Park to grow its operation in the Gateway’s BioHive hub as...
Recursion Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer
May 16, 2023 08:30 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, May 16, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has appointed...
Recursion firma acuerdos para la adquisición de Cyclica y Valence para fortalecer capacidades de química e IA generativa
May 09, 2023 19:34 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY y TORONTO y MONTREAL, May 09, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), una empresa líder de tecnobiología en etapa clínica con la decodificación de biología para la...
Recursion conclut des accords pour acquérir Cyclica et Valence en vue de renforcer ses capacités en chimie et de l'IA générative
May 09, 2023 19:34 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY, TORONTO et MONTRÉAL, 10 mai 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ : RXRX), une société de biotechnologie au stade clinique de premier plan qui décode la biologie pour...
Recursion schließt Übernahmevereinbarungen für Cyclica und Valence zur Stärkung der Fähigkeiten in den Bereichen Chemie und generative KI ab
May 09, 2023 19:34 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY und TORONTO und MONTRÉAL, May 10, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), ein führendes, im klinischen Stadium tätiges TechBio-Unternehmen, das die Biologie...
Recursion ने केमिस्ट्री और जनरेटिव AI क्षमताओं को सहारा देने हेतु Cyclica and Valence का अधिग्रहण करने के लिए समझौते किए
May 09, 2023 19:34 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY और TORONTO और MONTRÉAL, May 10, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), जो कि औषधि की खोज को औद्योगीकृत करने के लिए बाय़ोलॉजी को डिकोड करने वाली एक प्रमुख क्लीनिकल...
Recursion Provides Business Updates and Reports First Quarter 2023 Financial Results
May 08, 2023 08:14 ET
|
Recursion Pharmaceuticals
Entered into agreements to acquire Cyclica and Valence to bolster digital chemistry and generative AI capabilities in order to further create new chemical composition of matter for novel biological...
Recursion Enters into Agreements to Acquire Cyclica and Valence to Bolster Chemistry and Generative AI Capabilities
May 08, 2023 07:59 ET
|
Recursion Pharmaceuticals
SALT LAKE CITY and TORONTO and MONTRÉAL, May 08, 2023 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery,...